Pediatric anesthesia & critical care
Analysis of the factors contributing to residual weakness after sugammadex administration in pediatric patients under 2 years of age
Authors' conclusion
In this single-center, retrospective cohort study of pediatric surgery patients, there was an association between the hazard of sugammadex redose with both increased age and weight.
Study context
- Population
- Children aged ≤24 months undergoing surgery at a tertiary center (2018–2021) who received rocuronium and sugammadex reversalrecords reviewed
- Participants
- 2,923 children
- Outcome
- Sugammadex redose (recurarization risk)
Methodological detailssingle-center, survival analysis (Cox proportional hazards model)
- Single-center
- Survival analysis (Cox proportional hazards model)
Main finding
As reported in the abstract
Sugammadex redose
- Sugammadex redosed, cases
- 123 (4.2%)
- Time to redose, median [IQR], min
- 7 [4-17]
- Redose amount, median [IQR], mg/kg
- 2.74 [1.96-3.99]
- Increasing age associated with reduced hazard of redose
- p < .01
- Increasing weight associated with reduced hazard of redose
- p < .01
- Age 3 to 13 months (median weight): 53% risk reduction, HR
- 0.47 (0.24-0.91) (95% CI)
- Weight 4.7 to 9.2 kg (median age): 41% risk reduction, HR
- 0.59 (0.32-1.07) (95% CI)
Observational data: associations, not effects.
Original publication
Analysis of the factors contributing to residual weakness after sugammadex administration in pediatric patients under 2 years of age. Paediatr Anaesth. Published 4 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →